{"name":"APT Pharmaceuticals, Inc.","slug":"apt-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"APT Pharmaceuticals, Inc. is a biopharmaceutical company that was focused on developing innovative drug delivery systems, particularly for the treatment of respiratory diseases. The company's lead product, Cyclosporine Inhalation Solution (CIS), was discontinued, and there is limited public information available about its current status.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOWk5hTUlBVjBuS3UzQkRjNGJLVjdfX2pHX01wNzA3TGlWcHRpRGQwSFpQcndLaGFuLU5qNUVHSlNTWS1RdmRrb1Qzd09mZk02aC1UeExwaFhrVVJha0hCdUhqcUZBNjBkT1JjQmIzMW4zVWZSb0pMbDV2UU9FZlJacjVGdF9Jc2IySWZhcmZ0aU9nRFM3SUZhd1I1a0VCQQ?oc=5","date":"2025-12-08","type":"pipeline","source":"RTE.ie","summary":"Economy gets fatter from making the world slimmer - RTE.ie","headline":"Economy gets fatter from making the world slimmer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-25","type":"trial","source":"Express Pharma","summary":"US eosinophilic esophagitis market to reach $1.19 billion by 2030, forecasts GlobalData - Express Pharma","headline":"US eosinophilic esophagitis market to reach $1.19 billion by 2030, forecasts GlobalData","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPRl9HLS1vQkctdXpLWGhzX2NiSnRaeTZ1MWJIY0Nfd3otQU5fZC03WFhJV2VDbXJpcVhhQ0hNYW5UZWxibWFvdXJvUHloODdPVDdKd1FDMjJIcExQOVFxc2lOVURvdVVTRFA2anV6TkVLRFNUelRpR3JRZ0syT1ZxQVo2eFJfdDY4LWxuQTZB?oc=5","date":"2025-02-23","type":"pipeline","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025? - Yahoo Finance","headline":"Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBWUG1LY29uWVp4OUVUYWk4NVpIZW1zR2dyTlRDczlkbVZJUzdwamJYYl9DTjVrUkR6OGpBY2J5Zk1KZ3RiSzA0bFRzdVNlVDVsYUdvNXI0dGRlZGVXdi1UaUpmdDc1MHJG?oc=5","date":"2024-12-30","type":"pipeline","source":"Wiley Online Library","summary":"Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements - Wiley Online Library","headline":"Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcUpnSk5wUndITEp1TjNtZUlTQUF5cmVFRllXMmRiYTlTaHR5bTdpQnFKT1BJcGwtaUpmZXJzZXhlSHpmblI3akxvbm90NWNURDlIbnIyeUhnNG9HZzdqTjltNWdzek5ibEJ4ZWJ1Tm83Q3Q2T1FmTU50ZWJ4UUl2TGtsS01qRzJVbGV3?oc=5","date":"2024-11-26","type":"pipeline","source":"Life Science Leader","summary":"Companies To Watch: Terns Pharmaceuticals - Life Science Leader","headline":"Companies To Watch: Terns Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNZ3UtbGpGYUlwU0l2TTBIYUtsX2x5bUViR1Z0TEw5MkVTeWlSNk5wMF8xZ3pSZUl2RmZHdUJ0TjZJZ1Z3Q1NQQ0V2X2xfQnEzTmFFVlhBTDR0Tk1mdWVLZ2tLWjRpOHJETU9JV0t5UG8zY0lyLXBIeFNDaXhHWEo2WDZsZUo4RC1oUVJzWmkxLXVCMTQ2cjhIVXY0NXZxQUE?oc=5","date":"2024-09-27","type":"regulatory","source":"Plastics News","summary":"Aptar Pharma works with FDA on chemical-absorbing film, expands in New York - Plastics News","headline":"Aptar Pharma works with FDA on chemical-absorbing film, expands in New York","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOeU0yT2VOM3VuVUJkMWh2Qmd0RFprZHZvb3BuXzViZlQ5X3VXUTdzM2FFTTNzdU5tM1NxMnVyN1dUZDE1WkRzTzJCLXB4d3Z4RzctZ0pua0R5LTdNdUxZTll2VjluMjk4QXdOYW9MejR2bW44WFNOamY0UGt2WDhfZ0h4SUR4Mk9XaXFYMzFTYkhFem5ncHhjREllbnRjQ2tQSlE0QmFaR1Z5UUhtaFpwcE5nenZXTERGcUZxN0liWnA1UlFLa3BYVEttMzdOQnZCQTkxaVhDc3ZHU1VfSnAzT3FVanFBcldIbDBvd3E0SVpOeFRPTFBGajNIWWJiclhxMjAzajB0emJIZnl1TkZENHBTZVZtUQ?oc=5","date":"2023-06-13","type":"pipeline","source":"Business Wire","summary":"Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections - Business Wire","headline":"Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOVEhwWkFnNEFxT0VNNnZreGlTRzVBSEVzUmRDVUxsdGx3QTdYRXlVck9KRzYwU1FoVGc2NXJjUW1rNXRKaDNKMUJRVzRreE4xeVlZdmh5YkZXNFFGeEJPNUlOeGJFTGpsRjFqOWh1Zlk3VXR1eWdKNGpJSkg3RXozTUpldmxkRHhxT3Y4YnFoYmNoa0h6NkIzTHR2RFZGbTNQeFJVbA?oc=5","date":"2023-03-03","type":"regulatory","source":"Fierce Biotech","summary":"Chutes & Ladders—Billy Dunn departs FDA neuroscience team after 18 years - Fierce Biotech","headline":"Chutes & Ladders—Billy Dunn departs FDA neuroscience team after 18 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOMHNqRlRKU3FuUUNnOUdpRHZMOU91VzdjUnpxeVRyRC13aGZEaTFVNzNNTWlNWWxLQ29qZi1TMWVaNzk2MnVlXzhRMU5zYnEtOWRod1htRDBEeHJweVltZUtxV2xMc0hHcU03S1dudVBtUXJ2RVF6TjNwbm9JY2haWlBObUhzSmppbUtQYW5taVZLd01h?oc=5","date":"2022-07-19","type":"pipeline","source":"Pharma Voice","summary":"Pfizer’s former R&D head takes on drug pricing misconceptions in new book - Pharma Voice","headline":"Pfizer’s former R&D head takes on drug pricing misconceptions in new book","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPRUZCSWg4VkNldGUteUNIT0lkTHAxYWowYnQ2R3hJZUV2R2Z5ZjRHTU5BcVdTQUE1Ulh1V1FlN0l0REFUbk50R1g5STU0dFl0RTVrWURvcVJHeEQtM2lMT3FWNktiejJnZG9vZkZZV0NqQVhRaV8xQUlRVnc0NVNGLWRfaWZ1c0NkS1JUWmxaTFZUUlpyRXVCb201TU5vSHVROGc?oc=5","date":"2020-09-22","type":"pipeline","source":"tpg.com","summary":"TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis - tpg.com","headline":"TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPSGdqWWtHWlYxLVhlbjlLMUFnTmtyaWNMdTBqX0RFUVNBQ1lYZ2ZERGZ1LVhKbExtMDB1QTltdEJURU85cDdCc05XRWJBTFhFbHVuYVljZDBQV04zWk90SUd5Yk84RXNTM2tNNGRtWDFBRGRZaTNObjc5dE00b0xXN0FaRjQ?oc=5","date":"2017-01-05","type":"deal","source":"BioPharma Dive","summary":"AstraZeneca taps APT in latest deal - BioPharma Dive","headline":"AstraZeneca taps APT in latest deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNU196cEhNWHhLX0JOU2tNNVFhT2tLRG5sQWpBdGJxdDdpWTB0MjFTZkU4Wno4M1R1VVZyRkwwbmJ1T0xGQlAyU0lNbk9LLUVxMUhUZURQa3Z2OHFqcnQ2eGhoXzRRbHJQLWkxTnpsUW5qMGVQTW4wQVJYWndMdmlvMUt3U1VvVFN2SlFPaXo1c3k0MkgwMkVRNEpaRExpVnhKM3hEdVdybEw0d2JWTFdEamF6UzFpNHBueHZaUko0ZVg?oc=5","date":"2016-08-04","type":"pipeline","source":"PR Newswire","summary":"Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara - PR Newswire","headline":"Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}